NCT01494363Unknown2 期
Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 53
- 试验地点
- 6
- 主要终点
- Response rate
研究概览
简要总结
- Goals
The primary goal of this phase II trial is to:
evaluate the response rate of combination chemotherapy with Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan in patients with locally advanced or metastatic Biliary tract cancer as first-line chemotherapy
Secondary goals are to:
evaluate the treatment-related toxicities of this combination, investigate progression-free survival(PFS) and overall survival(OS) in this population 2. Design The proposed clinical trial is an open label, non-comparative, multicenter phase II trial according to the two stage testing design by Simon two-stage testing procedure
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who were diagnosed as adenocarcinoma of gallbladder or biliary tract histologically or cytologically
- •Unresectable locally advanced, metastatic, or recurrent biliary tract cancer
- •Patients must be ≥ 18 , ≤ 75 years old of age
- •ECOG performance status ≤ 2
- •At least one lesion that can be measured by imaging (CT/MRI) according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
- •Estimated life expectancy of more than 3 months
- •Adequate bone marrow function (absolute neutrophil count [ANC] ≥ 1,500/µL, hemoglobin ≥ 9.0 g/dL [correction by transfusion is acceptable], and platelets ≥ 100,000/µL)
- •Adequate kidney function (serum creatinine < 1.5 x upper limit of normal [ULN])
- •Adequate liver function (serum total bilirubin < 3.0xULN; serum transaminases levels < 5.0xUNL)
- •Provision of fully informed consent prior to any study specific procedures
排除标准
- •Other tumor type than adenocarcinoma
- •Any previous history of chemotherapy for biliary tract cancer (prior neoadjuvant/adjuvant chemotherapy is allowed, if recurrence occurred more than 6 months after completion of previous chemotherapy)
- •Patients with second primary cancer (except, adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥5 years)
- •Patients who received radiotherapy on target lesion within 6 months prior to study treatment
- •Patients with defect of central nervous system (CNS) or any psychiatric disorders and CNS metastases
- •Patients who received major surgery within 4 weeks of starting study treatment or was not recovered from any effects of major surgery
- •Pregnant or breastfeeding women and women of childbearing potential not employing adequate contraception
- •Other serious illness or medical conditions A. Clinically significant cardiac disease (uncontrolled congestive heart disease despite treatment [NYHA class III or IV], symptomatic coronary artery disease, unstable angina or myocardial infarction, conduction abnormality like grade 2 AV block, serious arrhythmia needed for medication, uncontrolled hypertension) within 6 months prior to study entry B. Liver cirrhosis (≥ Child-Pugh class B) C. History of significant neurologic or psychiatric disorders including dementia or seizures D. Active uncontrolled infection E. Other serious underlying medical conditions which could impair the ability of the patient to participate in the study
- •Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy
结局指标
主要结局
Response rate
时间窗: 2 years
Assessment of response will be assessed according to RECIST v1.1 criteria after completion of every two cycles. Evaluation will be conducted by physical examination, X-ray, or CT scan
次要结局
- Treatment-related toxicities(2 years)
- Progression free survival(2 years)
- Overall survival(2 years)
研究者
Nam Su Lee
Professor
Soon Chun Hyang University
研究点 (6)
Loading locations...
相似试验
已完成
2 期
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract CancerMetastatic Biliary Tract CancerNCT03524508Changhoon Yoo178
进行中（未招募）
2 期
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary CancerAdvanced Biliary Tract CancerNCT04005339Georgetown University48
已完成
2 期
Gemcitabine (GFF) in Patients With Pancreatic CancerMetastatic Pancreatic CancerNCT00919282CONKO-Studiengruppe78
终止
2 期
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell LymphomaMantle Cell LymphomaNCT00183989University of Southern California30
已完成
2 期
Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic LeukemiaB-cell LeukemiaChronic LeukemiaChronic Lymphocytic Leukemia (CLL)LeukemiaNCT00230282Steven E. Coutre25